United States Hereditary Angioedema Therapeutics Market to Grow at a CAGR of 8.20% During 2024-2032, Aided by the Increasing Diagnostics and Rising Awareness

Hereditary angioedema, a genetic disorder characterised by recurrent episodes of severe swelling in various body parts, poses a significant threat to patients' lives due to the deficiency or malfunction of the C1 inhibitor protein. With increasing accuracy in diagnostics and genetic mutations, the number of cases in the United States for hereditary angioedema has recorded a significant increase. In the United States, 15,000 to 30,000 emergency department admissions occur annually due to HAE episodes. However, advancements in therapies like Garadacimab offer effective management of the condition, driving growth of the United States hereditary angioedema therapeutics market.

Organizations like the United States Hereditary Angioedema Association play a crucial role in spreading awareness about the disease, its causes, and available treatments, aiding in early diagnosis and treatment. Home-based treatments have also emerged, alleviating the severity of attacks and enhancing patients' quality of life, leading to a growing adoption of hereditary angioedema therapeutics in the US market.

Rising research and development is supporting the growth of hereditary angioedema therapeutics market. For instance, in January 2024, Intellia Therapeutics published positive interim Phase 1 results for NTLA-2002 in patients with hereditary angioedema in the New England Journal of Medicine. The study showed that a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate across all 10 patients in the Phase 1 portion.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Drug Type and Route of Administration:

• The market is segmented based on drug type into C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, amongst others.

• Based on route of administration, the market can be divided into intravenous, subcutaneous, and oral.

Key Findings of the Report:

• Hereditary angioedema (HAE), characterized by recurrent severe swelling due to C1 inhibitor protein deficiency or malfunction, poses a significant threat to patients' lives, with 15,000 to 30,000 annual emergency department admissions in the United States.

• Advancements in therapies like Garadacimab offer effective management of HAE, contributing to the growth of the US hereditary angioedema therapeutics market.

• Organizations like the United States Hereditary Angioedema Association play a vital role in raising awareness about the disease and available treatments, facilitating early diagnosis and treatment.

• Home-based treatments have emerged as a valuable option for HAE patients, reducing the severity of attacks and improving their quality of life.

Key Offerings of the Report:

• The EMR report gives an overview of the United States hereditary angioedema therapeutics market for the periods (2017-2023) and (2024-2032).

• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the drug type, and route of administration of hereditary angioedema therapeutics.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the United States hereditary angioedema therapeutics market are Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Inc., Sanofi S.A., CSL Behring LLC., Pharming Group N.V., Cipla Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc. and Adverum Biotechnologies, Inc, amongst others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.